Overview

Gender

male

Investor Type

Investment Partner

Bill Burkoth is currently a Senior Director in Pfizer Ventures, the venture capital arm of Pfizer Inc.Since joining Pfizer in early 2004, Bill Burkoth has played an instrumental role in numerous new Pfizer venture investments, including Avid Radiopharmaceuticals (acquired by Eli Lilly), Evolution Benefits (acquired by Genstar Capital), and HandyLab (acquired by Becton Dickinson).Bill Burkoth currently serves on the Board of Directors of Aureon Biosciences, DVS Sciences and Novocure, and as a board observer of Clovis Oncology, HD Biosciences, M2S, and Nodality.

Prior to joining Pfizer, Bill Burkoth worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals.Prior to his roles in business development, Bill was an analyst at Bay City Capital, a leading life sciences venture capital firm. At Bay City, he evaluated numerous investment opportunities in biopharmaceuticals and assisted in the management of several portfolio companies.Bill Burkoth received a BA in chemistry from Whitman College and an MBA from Columbia Business School.